Fulcrum Therapeutics (FULC) Common Equity (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Common Equity for 9 consecutive years, with $310.7 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Common Equity rose 44.93% year-over-year to $310.7 million; the TTM figure through Jun 2026 stood at $310.7 million (up 44.93% YoY), while the FY2025 annual figure was $349.0 million, up 43.6% from the prior year.
• Common Equity declined to $310.7 million in Q2 2026 per FULC's latest filing, from $333.3 million in the prior quarter.
• Across five years, Common Equity topped out at $349.0 million in Q4 2025 and bottomed at $160.8 million in Q2 2022.
• Historically, Common Equity has averaged $247.5 million across 5 years, with a median of $239.1 million in 2023.
• Annual changes were most pronounced in 2023 — Common Equity soared 71.33% — and 2024, when it decreased 27.9%.
• Fulcrum Therapeutics' Common Equity stood at $198.9 million in 2022, then increased by 18.22% to $235.2 million in 2023, then climbed by 3.33% to $243.0 million in 2024, then jumped by 43.6% to $349.0 million in 2025, then declined by 10.98% to $310.7 million in 2026.
• Business Quant data shows FULC's Common Equity at $310.7 million in Q2 2026, $333.3 million in Q1 2026, and $349.0 million in Q4 2025.